ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2022
Biomarker-Based Lung Cancer Screening Eligibility: Implementation Considerations.
Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 8 citations in OpenAlex.
- Advances in modelling the risk of benign and malignant lung nodules.Frontiers in oncology · 2025Review
- Protein Biomarkers in Lung Cancer Screening: Technical Considerations and Feasibility Assessment.Archivos de bronconeumologia · 2024Review
- Lung cancer screening: where do we stand?Breathe (Sheffield, England) · 2024Review
- Design and methodological considerations for biomarker discovery and validation in the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Program.Annals of epidemiology · 2023Article
- Investigation on the incidence and risk factors of lung cancer among Chinese hospital employees.Thoracic cancer · 2022Article
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
With the convergence of promising biomarkers for lung cancer risk stratifications, and the increasing need for better eligibility assessment for lung cancer low-dose CT (LDCT) screening, the elephant in the room now is whether and how the implementation of biomarker-based lung cancer screening eligibility can be successfully achieved. This brief commentary provides an outline of key considerations for biomarker implementations for LDCT eligibility assessment and possible mitigation strategies. See related article by Jacobsen et al., p. 758.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.